With a market capitalization of $307.3 billion, Merck & Co., Inc. (MRK) develops and markets a broad portfolio of human health pharmaceuticals and vaccines in areas such as oncology, infectious diseases, cardiometabolic disorders and immunology, along with a strong animal health business serving livestock and companion animals.
Companies valued at more than $200 billion are generally classified as “mega-cap” stocks, and Merck & Co. fits this bill perfectly. The company also promotes innovation through strategic collaborations and licensing agreements with leading biopharmaceutical partners to develop next-generation therapies around the world.
Shares of the Rahway, New Jersey-based company have declined marginally from their 52-week high of $124.19. MRK stock has risen 23.5% over the past three months, outpacing the State Street Health Care Select Sector ETF SPDR (XLV)’s 1.9% gain over the same time period.
Longer term, the company’s shares have soared 35.9% over the past 52 weeks, compared to XLV’s 7.2% return over the same time period. Additionally, MRK stock is up 17.8% year-over-year, outpacing XLV’s 2.2% gain.
The stock has been trading above its 50- and 200-day moving averages since October 2025.
MRK stock rose 2.2% on February 3 after the company reported stronger-than-expected Q4 2025 adjusted EPS of $2.04 and revenue of $16.4 billion on February 3. Investors were encouraged by the continued strength of Keytruda, whose fourth-quarter sales rose 7% to $8.37 billion and full-year sales reached $31.7 billion.
By comparison, rival Amgen Inc. (AMGN) has lagged MRK stock. AMGN shares have returned 16.5% year to date and 23.1% over the past 52 weeks.
Despite the stock’s excellent performance, analysts remain cautiously optimistic about its prospects. MRK stock has a “Moderate Buy” consensus rating from 28 analysts in coverage, and the average price target of $126.76 is a 2.4% premium to current levels.
As of the date of publication, Sohini Mondal had no (directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com